Bank of Montreal Can Sells 58,422 Shares of LivaNova PLC (NASDAQ:LIVN)

Bank of Montreal Can lessened its stake in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 91.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,224 shares of the company's stock after selling 58,422 shares during the period. Bank of Montreal Can's holdings in LivaNova were worth $242,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Federated Hermes Inc. increased its holdings in shares of LivaNova by 1.3% in the 4th quarter. Federated Hermes Inc. now owns 142,893 shares of the company's stock worth $6,617,000 after purchasing an additional 1,823 shares in the last quarter. Russell Investments Group Ltd. boosted its position in shares of LivaNova by 17.1% during the fourth quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company's stock valued at $70,000 after buying an additional 219 shares during the last quarter. Envestnet Asset Management Inc. increased its holdings in LivaNova by 15.4% in the 4th quarter. Envestnet Asset Management Inc. now owns 43,932 shares of the company's stock worth $2,034,000 after buying an additional 5,850 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in LivaNova in the 4th quarter worth about $722,000. Finally, Wells Fargo & Company MN lifted its stake in LivaNova by 6.0% during the 4th quarter. Wells Fargo & Company MN now owns 220,782 shares of the company's stock valued at $10,224,000 after acquiring an additional 12,517 shares during the period. Hedge funds and other institutional investors own 97.64% of the company's stock.

LivaNova Trading Up 0.7 %

NASDAQ:LIVN traded up $0.25 during mid-day trading on Monday, hitting $37.51. 507,015 shares of the stock traded hands, compared to its average volume of 623,166. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. The stock has a market capitalization of $2.04 billion, a price-to-earnings ratio of 89.31 and a beta of 0.90. LivaNova PLC has a 52 week low of $32.48 and a 52 week high of $64.48. The firm's 50 day moving average is $38.94 and its two-hundred day moving average is $46.10.

Analysts Set New Price Targets

Several analysts recently commented on LIVN shares. Barclays cut their price objective on LivaNova from $58.00 to $56.00 and set an "equal weight" rating for the company in a report on Friday, March 7th. StockNews.com raised shares of LivaNova from a "buy" rating to a "strong-buy" rating in a research report on Tuesday, March 25th. Wolfe Research downgraded shares of LivaNova from an "outperform" rating to a "peer perform" rating in a report on Wednesday, February 26th. Mizuho cut their target price on shares of LivaNova from $70.00 to $60.00 and set an "outperform" rating for the company in a research report on Wednesday, February 26th. Finally, The Goldman Sachs Group dropped their price target on shares of LivaNova from $64.00 to $55.00 and set a "buy" rating on the stock in a research note on Monday, March 3rd. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, LivaNova presently has a consensus rating of "Buy" and an average target price of $61.17.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.